Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Viatris Inc.
Viatris’ attempts to deliver US generic versions of sitagliptin and sitagliptin/metformin ahead of patent expiry has failed for now, with an unfavorable judgment from a district court in West Virginia. More than 20 ANDA sponsors have opted to settle litigation with originator Merck.
In the coming days, Viatris expects to hear back from a court in West Virginia over its legal tussle with AstraZeneca on Symbicort IP. The US-based player has intimated that it may launch the product dependent on the court’s verdict.
Keeping Track: Terliprez, Sotyktu Keep Up US FDA’s Novel Approvals Pace; Submissions By Pfizer, Chiesi And BioLineRx
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker
GSK has lodged its opposition to Teva’s bid to resurrect long-running US litigation over “skinny-label” indication carve-outs at the Supreme Court level, claiming that Teva’s warnings of a “doomsday scenario” for generics are overstated.
- Generic Drugs
- Other Names / Subsidiaries
- Acton Pharmaceuticals, Inc.
- Agila, Bioniche Pharma Holdings Limited
- Alaven Pharmaceutical, LLC
- Antula Healthcare AB
- Dow B. Hickham
- Dow Hickam Pharmaceuticals, Inc.
- Generics (UK) Ltd.
- Jai Pharma
- Madaus Pharma
- Meda AB
- Meda Pharmaceuticals Inc.
- Mylan Inc.
- Mylan Laboratories Limited (formerly Matrix Laboratories Limited)
- Mylan Specialty (formerly Dey Pharma L.P.)
- Rottapharm Madaus
- Mylan Technologies, Inc.
- UDL Laboratories
- Viatris Inc.